Clario Tech

Clario delivers substantial gains toward diversity and net-zero emission goals in second annual ESG report

Retrieved on: 
Monday, December 11, 2023
Woman, Health equity, Research, Culture, FDA, Data collection, BYOD, Drug development, Biophysical environment, Electricity, ESG, Renewable energy, Clario Tech

Focus on health equity initiatives led to new patient-centric clinical trial approaches and advances in research into inclusivity in clinical trials.

Key Points: 
  • Focus on health equity initiatives led to new patient-centric clinical trial approaches and advances in research into inclusivity in clinical trials.
  • PHILADELPHIA, Dec. 11, 2023 /PRNewswire/ -- Clario , a healthcare research technology company that delivers the leading endpoint technology solutions for clinical trials, today released its second annual Environmental, Social, and Governance (ESG) report.
  • "Building upon the momentum from 2021, we are proud to publish Clario's second annual ESG report highlighting the substantial progress made towards our targets," said Chris Fikry, M.D., Chief Executive Officer at Clario.
  • To access Clario's second annual Environmental, Social, and Governance (ESG) report, go to Clario.com .

Clario delivers substantial gains toward diversity and net-zero emission goals in second annual ESG report

Retrieved on: 
Monday, December 11, 2023
Woman, Health equity, Research, Culture, FDA, Data collection, BYOD, Drug development, Biophysical environment, Electricity, ESG, Renewable energy, Clario Tech

Focus on health equity initiatives led to new patient-centric clinical trial approaches and advances in research into inclusivity in clinical trials.

Key Points: 
  • Focus on health equity initiatives led to new patient-centric clinical trial approaches and advances in research into inclusivity in clinical trials.
  • PHILADELPHIA, Dec. 11, 2023 /PRNewswire/ -- Clario , a healthcare research technology company that delivers the leading endpoint technology solutions for clinical trials, today released its second annual Environmental, Social, and Governance (ESG) report.
  • "Building upon the momentum from 2021, we are proud to publish Clario's second annual ESG report highlighting the substantial progress made towards our targets," said Chris Fikry, M.D., Chief Executive Officer at Clario.
  • To access Clario's second annual Environmental, Social, and Governance (ESG) report, go to Clario.com .

Clario's New AI-Powered ECG Quality Score Tool Enhances Cardiac Safety Assessments

Retrieved on: 
Tuesday, November 28, 2023
ECG, Quality Score, Insurance, Policy, Cohort (statistics), Medical device, Clario Tech

The AI-powered ECG Quality Score tool is a significant milestone in Clario's commitment to providing better accuracy and efficiency for cardiac safety assessments through technological advancement.

Key Points: 
  • The AI-powered ECG Quality Score tool is a significant milestone in Clario's commitment to providing better accuracy and efficiency for cardiac safety assessments through technological advancement.
  • By leveraging an AI/ML approach trained on over 80,000 Phase 1 Healthy Volunteer ECGs, the Quality Score tool provides detailed information on whether the acquired continuous ECG data is of sufficient quality for further EPQT.
  • Ellen Street, Executive Vice President, Cardiac Safety at Clario, expressed the company's enthusiasm, stating, "Clario's ECG Quality Score tool embodies our unwavering commitment to advancing trials and technologies through the use of AI/ML.
  • The ECG Quality Score tool includes two detailed reports – the Early Precision QT® Quality Summary Report and the Early Precision QT® Quality Detailed Report – which together provide granular information about the quality of ECG data collected.

Clario's New AI-Powered ECG Quality Score Tool Enhances Cardiac Safety Assessments

Retrieved on: 
Tuesday, November 28, 2023
ECG, Quality Score, Insurance, Policy, Cohort (statistics), Medical device, Clario Tech

The AI-powered ECG Quality Score tool is a significant milestone in Clario's commitment to providing better accuracy and efficiency for cardiac safety assessments through technological advancement.

Key Points: 
  • The AI-powered ECG Quality Score tool is a significant milestone in Clario's commitment to providing better accuracy and efficiency for cardiac safety assessments through technological advancement.
  • By leveraging an AI/ML approach trained on over 80,000 Phase 1 Healthy Volunteer ECGs, the Quality Score tool provides detailed information on whether the acquired continuous ECG data is of sufficient quality for further EPQT.
  • Ellen Street, Executive Vice President, Cardiac Safety at Clario, expressed the company's enthusiasm, stating, "Clario's ECG Quality Score tool embodies our unwavering commitment to advancing trials and technologies through the use of AI/ML.
  • The ECG Quality Score tool includes two detailed reports – the Early Precision QT® Quality Summary Report and the Early Precision QT® Quality Detailed Report – which together provide granular information about the quality of ECG data collected.

Clario's Oncology Webinar Series Part 3 -- Integrating Objectively Measured Safety Endpoints and Patient-Reported Outcomes in Oncology Trials: A Scientific Approach

Retrieved on: 
Wednesday, November 22, 2023
Safety, Patient safety, Consultant, Science, Pros, Medicine, Part, FDA, CVI, QT interval, MD, EST, Doctor of Philosophy, Oncology, Knowledge, Outline, Circulation: Cardiovascular Imaging, Drug development, Blood pressure, Nursing, Medical imaging, Clario Tech, Cardiology

TORONTO, Nov. 22, 2023 /PRNewswire-PRWeb/ -- In the ever-evolving landscape of drug development within oncology, the importance of collecting high-quality data across multiple endpoints cannot be overstated. This data plays a pivotal role in determining the success of a drug. The integration of objective safety measurements with patient-reported outcomes is now essential in characterizing a drug's safety profile, influencing overall benefit-risk considerations. Through this webinar, Clario invites you to explore our comprehensive scientific approach to enhancing safety and tolerability assessments in oncology trials.

Key Points: 
  • In this free webinar, Part 3 of Clario's Oncology Webinar Series, learn about a scientific approach to enhancing safety and tolerability assessments in oncology trials.
  • The integration of objective safety measurements with patient-reported outcomes is now essential in characterizing a drug's safety profile, influencing overall benefit-risk considerations.
  • Through this webinar, Clario invites you to explore our comprehensive scientific approach to enhancing safety and tolerability assessments in oncology trials.
  • For more information, or to register for this event, visit Clario's Oncology Webinar Series .

Electric vehicle (EV) battery market size to grow by USD 53.62 billion from 2022 to 2027, A123 Systems LLC, Ballard Power Systems Inc., BYD Co. Ltd. and more among the key companies in the market - Technavio

Retrieved on: 
Tuesday, November 21, 2023
Lithium, Safety, Research, EVS, Risk, Intelligence, USD, Benchmarking, BYD Han, BYD, Clario Tech, Electric vehicle, Growth, Electricity, EV, HEV, GC2, Electric battery, Fireworks, COVID-19

To learn more about the global trends impacting the future of market research, download a sample

Key Points: 
  • To learn more about the global trends impacting the future of market research, download a sample
    The growing global power crisis is challenging market growth.
  • The global demand for electricity to power EVs is increasing, with the expansion of the markets for hybrid electric vehicles (HEVs) and EVs.
  • Electric Vehicle (EV) Battery Market 2023-2027: Vendor Analysis
    We provide a detailed analysis of around 25 vendors operating in the EV battery market.
  • Electric Vehicle (EV) Battery Market 2023-2027: Key Highlights
    The light vehicle batteries market size is expected to increase by USD 34.06 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 12.72%.

Clario's Oncology Webinar Series Part 2 -- Using Scientific Validation to Move the Needle on Accessibility Functionalities, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, November 16, 2023
Science, Doctor of Philosophy, Clinical trial, Part, Consultant, Medical device, Nursing, Clario Tech

TORONTO, Nov. 16, 2023 /PRNewswire-PRWeb/ -- With the advance of technology, new opportunities to improve the clinical trial experience from a site and patient perspective come into existence. As regulatory bodies are demanding the use of accessibility functionality to improve inclusivity, Clario's scientific team is currently assessing the level of scientific research required to validate the use of accessibility features such as zoom in/zoom out and ensure data integrity is maintained.

Key Points: 
  • In this free webinar, Part 2 of Clario's Oncology Webinar Series, learn about new opportunities to improve the clinical trial experience from a site and patient perspective.
  • In the webinar, the presenters will discuss the accessibility features and present results to date on this industry's first study and provide insight into the next steps for accessibility functionalities.
  • This webinar is Part 2 of Clario's Oncology Webinar Series.
  • For more information, or to register for this event, visit Clario's Oncology Webinar Series .

Clario's Oncology Webinar Series Part 1 -- Revolutionizing Oncology Clinical Trials: The Transformative Power and Promise of AI-Enhanced Medical Imaging

Retrieved on: 
Thursday, November 9, 2023
Privacy, Artificial intelligence, Disease, AI, Development, Deep learning, Data science, Medical device, Medical imaging, Clario Tech

TORONTO, Nov. 9, 2023 /PRNewswire-PRWeb/ -- The integration of artificial intelligence (AI) with medical imaging in oncology clinical trials has brought about a profound transformation. Its advancements have revolutionized diagnostic accuracy and prognostic insights with advanced image segmentation methods enabling precise delineation of pathological areas and enhancing treatment response measurements. Furthermore, AI's predictive capabilities offer new avenues for anticipating disease progression and improving therapeutic strategies, all while ensuring patient privacy. Overall, the adoption of AI in oncology clinical trials promises a journey of innovation, encompassing precision diagnostics, predictive modeling and therapy evolution. This journey navigates complex aspects like patient privacy, data integrity and stakeholder engagement.

Key Points: 
  • In this free webinar, which is Part 1 of Clario's Oncology Webinar Series, learn about the current advancements of AI that are enhancing the efficiency of oncology clinical trials with a focus on medical imaging.
  • TORONTO, Nov. 9, 2023 /PRNewswire-PRWeb/ -- The integration of artificial intelligence (AI) with medical imaging in oncology clinical trials has brought about a profound transformation.
  • Esteemed speakers, Kim Nguyen, Joel Schaerer and Alex Boudreau, will explore how AI is transforming medical imaging for oncology-focused clinical trials.
  • For more information, or to register for this event, visit Clario's Oncology Webinar Series .

Clario presents a three-part webinar series on oncology trial solutions

Retrieved on: 
Tuesday, October 31, 2023
American Opportunity Tax Credit, Quality of life, FDA, Research, Safety, Clario Tech, Gait, Deep learning, EMA, Medical imaging, Medical device

PHILADELPHIA, Oct. 31, 2023 /PRNewswire/ -- Clario , a healthcare research technology company that delivers the leading endpoint technology solutions for clinical trials, announces a three-part educational webinar series on oncology trial solutions.

Key Points: 
  • PHILADELPHIA, Oct. 31, 2023 /PRNewswire/ -- Clario , a healthcare research technology company that delivers the leading endpoint technology solutions for clinical trials, announces a three-part educational webinar series on oncology trial solutions.
  • Drawing from over 50 years of clinical trial expertise, Clario's webinars will focus on improving the assessment of efficacy, safety and quality of life within oncology clinical trial development programs.
  • Part one of the series will delve into the current advancements of AI that are enhancing the efficiency of oncology clinical trials with a focus on medical imaging.
  • "We are delighted to introduce Clario's new three-part educational webinar series on oncology trial solutions.

Clario presents a three-part webinar series on oncology trial solutions

Retrieved on: 
Tuesday, October 31, 2023
American Opportunity Tax Credit, Quality of life, FDA, Research, Safety, Clario Tech, Gait, Deep learning, EMA, Medical imaging, Medical device

PHILADELPHIA, Oct. 31, 2023 /PRNewswire/ -- Clario , a healthcare research technology company that delivers the leading endpoint technology solutions for clinical trials, announces a three-part educational webinar series on oncology trial solutions.

Key Points: 
  • PHILADELPHIA, Oct. 31, 2023 /PRNewswire/ -- Clario , a healthcare research technology company that delivers the leading endpoint technology solutions for clinical trials, announces a three-part educational webinar series on oncology trial solutions.
  • Drawing from over 50 years of clinical trial expertise, Clario's webinars will focus on improving the assessment of efficacy, safety and quality of life within oncology clinical trial development programs.
  • Part one of the series will delve into the current advancements of AI that are enhancing the efficiency of oncology clinical trials with a focus on medical imaging.
  • "We are delighted to introduce Clario's new three-part educational webinar series on oncology trial solutions.